Recursion Pharmaceuticals, Inc. (RXRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $3.09. The rating moved from Neutral to Oversold on August 19, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$3.09
• Last changeMoved from Neutral to Oversold on August 19, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Recursion combines an AI-enabled discovery platform with a pipeline and partnership optionality that support long-term upside, but near-term fundamentals are dominated by cash burn, execution and clinical-readout risk. Market sentiment toward AI and biologics manufacturing provides a constructive thematic backdrop, yet the company remains exposed to dilution and binary trial outcomes. Expect subdued near-term trading with upside driven by tangible partnership progress, positive translational data, or clearer cash-runway extension.

Key factors

• Proprietary AI/automation drug-discovery platform that can drive discovery efficiency and de-risk early-stage programs
• Diversified pipeline and collaborations that provide optionality across multiple therapeutic areas
• Sector environment showing increased interest in AI and biologics which could enhance strategic partner demand and valuation re-rating
• Current share price reflects a low market valuation that partially prices in clinical and execution risk
• Potential for non-dilutive partnership, licensing, or CDMO tailwinds given broader biologics demand

Risks

• Ongoing cash burn and the likelihood of future equity financing that could dilute existing shareholders
• High clinical and regulatory risk inherent to early-stage biopharma programs; negative trial data would materially impair valuation
• Competitive pressure from larger pharma, established CRO/CDMO players, and other AI-driven discovery companies
• Execution risk integrating data, automation, and translational pipelines at scale; platform underperformance would reduce commercial prospects
• Market volatility and sentiment swings in small-cap biotech that can amplify downside unrelated to fundamentals

Latest MarketMoodz coverage

• Goldman Bets Nvidia Gains From Healthcare AI Push2026-03-31

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.